Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by whcon Jun 10, 2020 12:16am

191 Views

Post# 31131807

RE:RE:RE:RE:RE:RE:People's Poll - Adjusting for Risk - Market Price June 10

You're right, big pharma won't buy just anything but this is for pain management. When people are in pain they are going to buy your product, recession or not. Big pharma makes billions every year and spend billions in research that often fail. And here we have a drug that's just been derisked and Dan can't get a bidding war going?

Bullboard Posts

HPQ Silicon updates shareholders on Fumed Silica Reactor developments